L-type calcium channel blockers may increase risk for heart failure, study finds

Written By :  Dr. Kamal Kant Kohli
Published On 2020-07-27 06:45 GMT   |   Update On 2020-07-27 06:45 GMT
Advertisement

UNIVERSITY PARK, Pa. --L-type Calcium channel blockers (LCCBs) represent a large family of drugs most widely used drugs used in the clinic for over 70 y to treat hypertension, angina, and cardiac arrhythmias. 

According to a new study they may harm the heart as much as help it and may lead to greater risk for heart failure.

Researchers at Penn State have found that in rats and human cells in vitro, LCCBs cause changes in blood vessels -- known as vascular remodeling -- that reduce blood flow and increase pressure. Examining epidemiological data, the team also found that LCCBs are associated with a greater risk for heart failure.Their results have been published in Proceedings of the National Academy of Sciences.

The findings suggest that care should be taken when prescribing these drugs to patients, particularly older adults and those with advanced hypertension.

"In the United States, nearly half of all adults -- or just over a hundred million -- have hypertension, and its prevalence is increasing; worldwide, the condition is expected to affect 1.56 billion people by 2025," said Mohamed Trebak, professor of cellular and molecular physiology, Penn State. "L-type calcium channel blockers are one of the most widely prescribed drugs to treat hypertension, yet we have found that these drugs may cause the same type of damage they are intended to prevent."

Trebak explained that vascular smooth muscle cells (VSMCs) make up the walls of blood vessels, where they help the vessels to control blood flow by contracting and relaxing. This activity is regulated by the concentration of calcium within the cells. VSMCs contain numerous calcium-permeable channels to control this calcium concentration. Under conditions of hypertension, these channels allow too much calcium to enter VSMCs, which triggers the cells to undergo physiological changes, known as "remodeling," and to divide and proliferate. These remodeled, proliferative cells cause blood vessel walls to thicken and stiffen and blood pressure to rise.

"L-type calcium channel blockers were created to prevent this from happening," said Trebak. "Yet, we found that these drugs also simultaneously cause remodeling and proliferation of VSMCs through another mechanism."

To investigate the specific mechanisms by which LCCBs affect VSMCs, Trebak and his colleagues used optical, electrophysiological and molecular tools to examine smooth muscle cells in vitro and in rats.

The team found that calcium entry into VSMCs is mediated by stromal-interacting molecule (STIM) proteins activating ORAI calcium channels and that chronic exposure to LCCBs causes these STIM proteins to become overactive, which triggers VSMCs to proliferate. 

Additionally, the researchers examined epidemiological data from the Penn State clinical database and found that incidences of heart failure were significantly higher in hypertensive patients treated with LCCBs than in hypertensive patients treated with other types of hypertension medications.

"Treatment with LCCBs is clinically associated with elevated incidence of heart failure, which prompts a careful examination of the use of LCCBs during chronic hypertension where vascular remodeling is evident," said Trebak. "Extra care should be taken when hypertensive patients present with COVID-19, as LCCBs may exacerbate their vascular damage.

for further references log on to: 

http://dx.doi.org/10.1073/pnas.2007598117

Tags:    
Article Source : Proceedings of the National Academy of Sciences

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News